8-K: Regeneron Reports Strong Q4 and Full Year 2024 Results, Initiates Dividend and Boosts Share Repurchase Program

Regeneron announces a 10% increase in Q4 revenues and the initiation of a quarterly dividend program alongside an expanded share repurchase authorization.

Summary

• Regeneron Pharmaceuticals reported its financial results for the fourth quarter and full year 2024.
• Q4 2024 revenues increased by 10% to $3.79 billion compared to Q4 2023.
• Full year 2024 revenues grew by 8% to $14.20 billion versus 2023.
• Excluding Ronapreve, revenues increased by 10%.
• Dupixent global net sales (recorded by Sanofi) increased 15% to $3.70 billion in Q4 2024 and 22% to $14.15 billion for the full year.
• EYLEA HD and EYLEA U.S. net sales increased 2% in Q4 2024 to $1.50 billion, including $305 million from EYLEA HD.
• Full year 2024 U.S. net sales for EYLEA HD and EYLEA increased 1% to $5.97 billion, including $1.20 billion from EYLEA HD.
• Libtayo global net sales increased 50% to $367 million in Q4 2024 and 40% to $1.22 billion for the full year.
• Q4 2024 GAAP diluted EPS was $8.06 and non-GAAP diluted EPS was $12.07, which includes an unfavorable $0.11 impact from an acquired IPR&D charge.
• The company initiated a quarterly cash dividend program, declaring a $0.88 dividend per share.
• An additional $3.0 billion share repurchase program was authorized, bringing the total repurchase capacity to approximately $4.5 billion.
• Regulatory applications were submitted to the FDA for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, odronextamab in follicular lymphoma, and linvoseltamab in multiple myeloma.
• Positive Phase 3 results were reported for EYLEA HD in retinal vein occlusion (RVO) and Libtayo in high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).

Sentiment

Score: 8

Explanation: The report is positive due to strong revenue growth, successful product performance, and shareholder-friendly actions like dividends and share repurchases. However, some concerns exist regarding increased expenses and competition.

Positives

• Strong revenue growth in Q4 and full year 2024.
• Significant increase in Dupixent and Libtayo sales.
• Successful launch of EYLEA HD, contributing to overall EYLEA sales.
• Initiation of a quarterly cash dividend program, returning capital to shareholders.
• Increase in share repurchase authorization, indicating confidence in the company's future.
• Positive clinical trial results for EYLEA HD and Libtayo, supporting potential label expansions.
• Regulatory submissions for multiple products and indications, suggesting a robust pipeline.

Negatives

• GAAP net income decreased by 21% in Q4 2024.
• EYLEA U.S. sales decreased by 11% in Q4 2024.
• Inmazeb U.S. sales decreased by 35% in Q4 2024.
• Net product sales of EYLEA HD and EYLEA in the fourth quarter and full year 2024 were adversely impacted by a lower net selling price compared to the same periods of 2023.
• GAAP other income (expense), net included the recognition of net unrealized losses on equity securities of $213 million in the fourth quarter of 2024.

Risks

• The company's 2025 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release.
• The company faces risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc.
• There are risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations.
• There are risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA).

Future Outlook

Regeneron anticipates continued investment in its R&D pipeline and returning capital to shareholders through dividends and share repurchases. The company will focus on its four blockbuster medicines and progress its approximately 40 investigational candidates.

Management Comments

• Regeneron's financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity, said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.
• In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of disease states with expansive market potential, said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.
• 2024 was another year of topand bottom-line growth for Regeneron, said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron.
• This strong financial performance, coupled with the strength of our balance sheet, allows us to initiate a quarterly cash dividend program as well as increase our current share repurchase capacity to approximately $4.5 billion, said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron.

Industry Context

Regeneron's performance reflects the ongoing demand for its key products like Dupixent and EYLEA, and its strategic focus on developing innovative therapies. The initiation of a dividend program signals a mature phase for the company, aligning it with other established players in the biotechnology industry. The expanded share repurchase program further underscores management's confidence in the company's future prospects.

Comparison to Industry Standards

• Regeneron's revenue growth of 8% for the full year 2024 is comparable to other large-cap pharmaceutical companies such as Johnson & Johnson and Pfizer, although specific growth rates vary depending on product portfolios and market conditions.
• The 22% growth in Dupixent sales is particularly strong, indicating its continued market penetration and success in various indications; this growth rate exceeds that of many competing biologics in the immunology space.
• The initiation of a quarterly dividend program aligns Regeneron with established pharmaceutical companies that prioritize returning capital to shareholders, such as AbbVie and Merck.
• The authorization of a $4.5 billion share repurchase program is a significant capital allocation decision, similar in scale to repurchase programs announced by other large-cap companies like Amgen and Gilead Sciences.

Stakeholder Impact

• Shareholders will benefit from the initiation of a quarterly dividend and the increased share repurchase program.
• Patients may benefit from potential new therapies and expanded indications for existing drugs.
• Employees may benefit from the company's continued growth and investment in R&D.

Next Steps

• Submit sBLA for EYLEA HD in RVO in the first quarter of 2025.
• Await FDA decision on sBLA for EYLEA HD with two-year data for wAMD and DME (target action date of April 20, 2025).
• Submit sBLA for EYLEA HD for every 4-week dosing regimen in the first quarter of 2025.
• Report results from Phase 3 study for itepekimab in COPD in the second half of 2025 and submit BLA.
• Await FDA decision on sBLA for Dupixent in CSU (target action date of April 18, 2025).
• Await sBLA acceptance for Dupixent in bullous pemphigoid in the first half of 2025 and FDA decision in the second half of 2025; regulatory submission in EU in the first half of 2025.
• Initiate additional Phase 3 studies for itepekimab in the first half of 2025.
• Report additional data from Phase 1 study for linvoseltamab in combination with Dupixent in severe food allergies.
• Submit sBLA for Libtayo in adjuvant CSCC in the first half of 2025.
• Report results from Phase 3 study of fianlimab in combination with Libtayo versus pembrolizumab in first-line metastatic melanoma in the second half of 2025 and submit BLA.
• Report initial Phase 2 data for fianlimab in combination with Libtayo in first-line advanced NSCLC in the first half of 2025.
• Report additional data for ubamatamab in ovarian cancer.
• Report additional data from solid tumor costimulatory bispecific antibody programs.
• Await FDA decision on BLA for odronextamab in R/R follicular lymphoma in the second half of 2025.
• Await FDA decision on BLA for linvoseltamab in R/R multiple myeloma in mid-2025.
• Initiate Phase 3 program for Factor XI antibodies (REGN9933 and REGN7508).
• Report additional data from Phase 1/2 study for DB-OTO in patients with hearing deficit due to variants of the otoferlin gene in mid-2025.
• Report results from Phase 3 study for pozelimab in combination with cemdisiran in myasthenia gravis in the second half of 2025.
• Report results from Phase 2 study for semaglutide in combination with trevogrumab with and without garetosmab in obesity in the second half of 2025.
• Report results from Phase 2 study for mibavademab in combination with tirzepatide in obesity in the second half of 2025.
• Report results from Phase 3 study for garetosmab in fibrodysplasia ossificans progressiva (FOP) in the second half of 2025.

Key Dates

Keywords

Regeneron, Financial Results, Dividend, Share Repurchase, Dupixent, EYLEA HD, Libtayo, Revenue, Earnings, Pharmaceuticals